In last trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 1.57 million shares changing hands with its beta currently measuring 1.04. Company’s recent per share price level of $1.85 trading at -$0.05 or -2.63% at ring of the bell on the day assigns it a market valuation of $364.52M. That closing price of ESPR’s stock is at a discount of -112.97% from its 52-week high price of $3.94 and is indicating a premium of 14.59% from its 52-week low price of $1.58.
For Esperion Therapeutics Inc (ESPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.78. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.16 in the current quarter.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Upright in the red during last session for losing -2.63%, in the last five days ESPR remained trading in the red while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $1.85 price level, adding 4.15% to its value on the day. Esperion Therapeutics Inc’s shares saw a change of -15.91% in year-to-date performance and have moved -1.60% in past 5-day. Esperion Therapeutics Inc (NASDAQ:ESPR) showed a performance of -13.95% in past 30-days.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 76.88% to its current value. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -332.43% in reaching the projected high whereas dropping to the targeted low would mean a loss of -332.43% for stock’s current value.
Esperion Therapeutics Inc (ESPR) estimates and forecasts
This year revenue growth is estimated to rise 179.14% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 61.58M for the same. And 5 analysts are in estimates of company making revenue of 50.64M in the next quarter. Company posted 32.25M and 137.74M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 23.09% during past 5 years.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
WASATCH ADVISORS LP is the top institutional holder at ESPR for having 16.86 million shares of worth $37.44 million. And as of 2024-06-30, it was holding 8.9319 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 13.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.2617 of outstanding shares, having a total worth of $31.04 million.
